1. Van Nostrand D, Khorjekar GR, O'Neil J, et al. Recombinant human thyroidstimulating
hormone versus thyroid hormone withdrawal in the identification of metastasis in …

The response of the PSA level was as follows: for group A, PSA decreased in 26.3%, did not
change in 5.3%, and increased in 68.4%; for group B, PSA decreased in 15.8%, did not …

562 Introduction: Radium 223 is indicated for the treatment of symptomatic bone metastases
from castration-resistant prostate cancer. The aim of this trial was to evaluate the efficacy of …

This retrospective study compared the effects of single and multiple administrations of
186Re-hydroxyethylidenediphosphonate (186Re-HEDP) on palliation and survival of …

Objective: Our objective was to investigate the clinical efficacy of 131I therapy for bone
metastases from differentiated thyroid cancer (DTC) and prognostic factors as well as to …

Purpose This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223
in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) …

TO THE EDITOR: Distant metastases are found at diagnosis or during follow-up in 10%–
15% of patients with differentiated thyroid cancer. Bone is the second most commonly …

Background: The objective of this study was to evaluate the overall survival (OS) of
radioiodine (131I) treatments alone or combined with non-131I treatments in patients with …

4. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid
cancer patients. Br J Cancer. 2003; 89: 1638–1644. 5. Deandreis D, Schlumberger M, Tuttle …

TO THE EDITOR: Deandreis et al.(1) compared the overall survival (OS) of 2 patient groups
with metastatic differentiated thyroid cancer (mDTC). One group of patients underwent …